NBQX disodium salt
NBQX disodium salt is a potent, highly selective and competitive antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors (AMPARs). The AMPAR is one type of ionotropic glutamate receptors, well known to be involved in various neurological disorders such as Alzheimer disease, schizophrenia, and epilepsy, by mediating long-term potentiation, excitotoxicity, or both. Inhibition of AMPARs with NBQX shows neuroprotective and anticonvulsant activity.
References:
1. Fukushima K, Tabata Y, Imaizumi Y, et al. Characterization of human hippocampal neural stem/progenitor cells and their application to physiologically relevant assays for multiple ionotropic glutamate receptors. Journal of Biomolecular Screening, 2014, 19(8): 1174-1184.
2. Chen W, Li YS, Gao J, et al. AMPA Receptor Antagonist NBQX Decreased Seizures by Normalization of Perineuronal Nets. PLoS One, 2016, 11(11): e0166672.
| Physical Appearance | A crystalline solid |
| Storage | Store at -20°C |
| M.Wt | 380.24 |
| Cas No. | 479347-86-9 |
| Formula | C12H6N4O6SNa2 |
| Solubility | Soluble in H2O |
| Chemical Name | sodium 6-nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-bis(olate) |
| SDF | Download SDF |
| Canonical SMILES | O=S(N)(C1=CC=CC2=C1C([N+]([O-])=O)=CC(N=C3[O-])=C2N=C3[O-])=O.[Na+].[Na+] |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
|
Cell lines |
HIP-009 cells |
|
Reaction Conditions |
1 h incubation |
|
Applications |
NBQX inhibited both AMPA or kainic acid (KA) induced signals in a concentration-dependent manner, with IC50 values being 0.7 ± 0.1 and 0.7 ± 0.03 µM, respectively. The AMPA-evoked calcium rise was completely inhibited by NBQX, whereas 68.6% ± 1.3% inhibition of the KA-induced signal was observed with 30 μM of NBQX treatment. |
| Animal experiment:[2] | |
|
Animal models |
Male Wistar rats intraperitoneally injected with pentylenetetrazole |
|
Dosage form |
20 mg/kg Once daily by intraperitoneal injection for 3 days |
|
Applications |
NBQX was sufficient to decrease pentylenetetrazole-induced seizures through increasing the latency to seizures, decrease the duration of seizure onset, and reduce the scores for the severity of seizures. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Fukushima K, Tabata Y, Imaizumi Y, et al. Characterization of human hippocampal neural stem/progenitor cells and their application to physiologically relevant assays for multiple ionotropic glutamate receptors. Journal of Biomolecular Screening, 2014, 19(8): 1174-1184. 2. Chen W, Li YS, Gao J, et al. AMPA Receptor Antagonist NBQX Decreased Seizures by Normalization of Perineuronal Nets. PLoS One, 2016, 11(11): e0166672. |
|
Quality Control & MSDS
- View current batch:
-
Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
Chemical structure
